MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 77 filers reported holding MARINUS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.31 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,381,032 | -21.2% | 2,904,476 | +6.3% | 0.05% | -17.2% |
| Q2 2023 | $29,661,375 | +111.3% | 2,731,250 | +34.2% | 0.06% | +106.5% |
| Q1 2023 | $14,038,050 | +71.8% | 2,034,500 | -0.9% | 0.03% | +55.0% |
| Q4 2022 | $8,168,950 | -0.7% | 2,052,500 | +65.9% | 0.02% | 0.0% |
| Q3 2022 | $8,229,000 | +34.7% | 1,237,500 | -2.0% | 0.02% | +42.9% |
| Q2 2022 | $6,111,000 | -48.2% | 1,262,500 | 0.0% | 0.01% | -36.4% |
| Q1 2022 | $11,804,000 | -21.3% | 1,262,500 | 0.0% | 0.02% | -18.5% |
| Q4 2021 | $14,999,000 | +4.4% | 1,262,500 | 0.0% | 0.03% | -3.6% |
| Q3 2021 | $14,367,000 | -36.6% | 1,262,500 | 0.0% | 0.03% | -36.4% |
| Q2 2021 | $22,649,000 | +0.0% | 1,262,500 | -13.7% | 0.04% | -4.3% |
| Q1 2021 | $22,640,000 | +26.9% | 1,462,500 | 0.0% | 0.05% | +17.9% |
| Q4 2020 | $17,843,000 | -5.1% | 1,462,500 | 0.0% | 0.04% | -17.0% |
| Q3 2020 | $18,793,000 | – | 1,462,500 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,629,622 | $41,305,000 | 7.74% |
| VR Adviser, LLC | 2,641,809 | $30,064,000 | 3.86% |
| Bleichroeder LP | 1,062,500 | $12,091,000 | 1.96% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $16,285,000 | 1.01% |
| Boxer Capital, LLC | 2,400,000 | $27,312,000 | 0.95% |
| 683 Capital Management, LLC | 1,929,929 | $21,963,000 | 0.86% |
| Avoro Capital Advisors LLC | 3,235,000 | $36,814,000 | 0.58% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,197,426 | $25,007,000 | 0.42% |
| Granite Point Capital Management, L.P. | 419,324 | $4,772,000 | 0.36% |
| KNOTT DAVID M | 81,166 | $924,000 | 0.34% |